[go: up one dir, main page]

PE20000325A1 - Derivados de 2-ariletil-(piperidin-4-ilmetil)amina - Google Patents

Derivados de 2-ariletil-(piperidin-4-ilmetil)amina

Info

Publication number
PE20000325A1
PE20000325A1 PE1999000155A PE00015599A PE20000325A1 PE 20000325 A1 PE20000325 A1 PE 20000325A1 PE 1999000155 A PE1999000155 A PE 1999000155A PE 00015599 A PE00015599 A PE 00015599A PE 20000325 A1 PE20000325 A1 PE 20000325A1
Authority
PE
Peru
Prior art keywords
alkyl
piperidin
amine
haloalkyl
cycloalkyl
Prior art date
Application number
PE1999000155A
Other languages
English (en)
Inventor
Hans Maag
David Bruce Repke
Robin Douglas Clark
Michael Patrick Dillon
Sharathchandra Surendra Hegde
Clara Jeou Jen Lin
Iii Ralph New Harris
Joan Marie Caroon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20000325A1 publication Critical patent/PE20000325A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE: R1 ES H, ALQUILO, ALQUILOXI, HALOGENO, HALOALQUILO, AMINO; R2 ES ALQUILO, ALQUILOXILO, HALOGENO, HALOALQUILO, -O(CH2)pX, -NR7R8, -NR6COR9, ENTRE OTROS; p ES 0-6; X ES HALOALQUILO, ARILO; O R1 Y R2 FORMAN UN ANILLO MONOCICLICO DE 5-6 MIEMBROS; R3 Y R4 SON ALQUILO, ALQUENILO, CICLOALQUILO; R5 ES H, -COR9, -COOR7, -CONR7R8, -CO(CH2)nCOR9, -CO(CH2)nSO2R9, -CO(CH2)nCONR7R8, -CSR9, -SO2NR6(CH2)nCOOR7, ENTRE OTROS; R6 Y R7 SON H o ALQUILO, R8 ES H, ALQUILO, CICLOALQUILO, ARILO, HETEROARILO; R9 ES ALQUILO, CICLOALQUILO, ARILALQUILO, ARILO, HETEROCICLO, HETEROARILO, ENTRE OTROS; n ES 1-6. SON COMPUESTOS PREFERIDOS N-[2-(2,3-DIHIDROBENZOFURAN-5-IL)-1-METILETIL]-N-ETIL-(1-METANSULFONIL-PIPERIDIN-4-ILMETIL)AMINA; N-[2-(2,3-DIHIDROBENZOFURAN-5-IL)-1-METILETIL]-N-PROPIL-(1-METANSULFONIL-PIPERIDIN-4-[ILMETIL]AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES ANTAGONISTA DEL RECEPTOR MUSCARINICO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, DEL TRACTO GENITOURINARIO, DEL TRACTO RESPIRATORIO, SISTEMA CARDIOVASCULAR, SISTEMA NERVIOSO CENTRAL
PE1999000155A 1998-02-27 1999-02-23 Derivados de 2-ariletil-(piperidin-4-ilmetil)amina PE20000325A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7611398P 1998-02-27 1998-02-27
US10909798P 1998-11-19 1998-11-19

Publications (1)

Publication Number Publication Date
PE20000325A1 true PE20000325A1 (es) 2000-05-08

Family

ID=26757679

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000155A PE20000325A1 (es) 1998-02-27 1999-02-23 Derivados de 2-ariletil-(piperidin-4-ilmetil)amina

Country Status (27)

Country Link
US (1) US6319920B1 (es)
EP (1) EP1058680B1 (es)
JP (1) JP3523198B2 (es)
KR (1) KR100384906B1 (es)
CN (1) CN1143848C (es)
AR (1) AR015523A1 (es)
AT (1) ATE400554T1 (es)
AU (1) AU753255B2 (es)
BR (1) BR9909253A (es)
CA (1) CA2321198C (es)
CO (1) CO4990939A1 (es)
DE (1) DE69939053D1 (es)
ES (1) ES2310032T3 (es)
HK (1) HK1036623A1 (es)
HR (1) HRP20000544A2 (es)
HU (1) HUP0100760A3 (es)
IL (1) IL137936A0 (es)
MA (1) MA26610A1 (es)
MY (1) MY133445A (es)
NO (1) NO317106B1 (es)
NZ (1) NZ506317A (es)
PE (1) PE20000325A1 (es)
PL (1) PL194037B1 (es)
RU (1) RU2220138C2 (es)
TR (1) TR200002481T2 (es)
WO (1) WO1999043657A1 (es)
YU (1) YU53100A (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012150A4 (en) * 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
CA2409841C (en) 2000-05-25 2009-04-14 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA02011417A (es) 2000-05-25 2003-04-25 Hoffmann La Roche 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
CA2468691C (en) 2001-12-03 2011-03-08 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
WO2003048125A1 (en) 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonists
BR0311414A (pt) * 2002-06-07 2005-03-15 Yamanouchi Pharma Co Ltd Agente terapêutico para uma bexiga hiperativa
WO2004004629A2 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60315258T2 (de) * 2002-12-20 2008-05-08 Dynogen Pharmaceuticals Inc., Waltham Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
CA2519694A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070021487A1 (en) 2003-04-11 2007-01-25 Mohammad Salman Azabicyclo derivatives as muscarinic receptor antagonists
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
US7214439B2 (en) * 2003-12-19 2007-05-08 Millennium Cell, Inc. Triborohydride salts as hydrogen storage materials and preparation thereof
CN101663270B (zh) 2007-04-24 2013-07-17 施万制药 可用作蕈毒碱受体拮抗剂的季铵化合物
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP3170807B1 (en) * 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
SI25272A (sl) 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) * 2019-11-20 2021-05-21 珠海润都制药股份有限公司 一种盐酸坦索罗辛的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924751T2 (de) 1988-09-26 1996-04-11 Smithkline Beecham Farma Azacyclische Verbindungen, verwendbar als Arzneimittel.
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
JP3064425B2 (ja) 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ カルシウムチャンネル・ブロッカーとしてのピペリジン化合物
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
AR015523A1 (es) 2001-05-02
TR200002481T2 (tr) 2000-11-21
YU53100A (sh) 2003-04-30
HUP0100760A3 (en) 2002-12-28
AU2835399A (en) 1999-09-15
WO1999043657A1 (en) 1999-09-02
PL342692A1 (en) 2001-07-02
US6319920B1 (en) 2001-11-20
RU2220138C2 (ru) 2003-12-27
NO20004261D0 (no) 2000-08-25
EP1058680A1 (en) 2000-12-13
CO4990939A1 (es) 2000-12-26
JP2002504543A (ja) 2002-02-12
CA2321198A1 (en) 1999-09-02
IL137936A0 (en) 2001-10-31
MY133445A (en) 2007-11-30
ES2310032T3 (es) 2008-12-16
JP3523198B2 (ja) 2004-04-26
PL194037B1 (pl) 2007-04-30
NO20004261L (no) 2000-08-25
AU753255B2 (en) 2002-10-10
ATE400554T1 (de) 2008-07-15
EP1058680B1 (en) 2008-07-09
CN1295563A (zh) 2001-05-16
HUP0100760A2 (hu) 2001-08-28
BR9909253A (pt) 2000-11-28
CN1143848C (zh) 2004-03-31
KR20010041321A (ko) 2001-05-15
CA2321198C (en) 2009-11-17
KR100384906B1 (ko) 2003-05-23
HRP20000544A2 (en) 2001-02-28
MA26610A1 (fr) 2004-12-20
HK1036623A1 (en) 2002-01-11
NZ506317A (en) 2003-08-29
NO317106B1 (no) 2004-08-09
DE69939053D1 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
EP1257547B1 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20001088A1 (es) Compuestos derivados de tetrahidrobenzazepina
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
MX9504349A (es) Derivados de aroilpiperidina.
PE20020332A1 (es) Derivados de 4-fenil-piridina como antagonistas de receptores de neuroquinina nk-1
PT526434E (pt) Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2.
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
YU59901A (sh) Derivati 3-fenilpiridina i njihova primena kao antagonista nk-1 receptora
PE20100093A1 (es) Derivados de acetileno
KR900014321A (ko) 신경변성 질환에 유용한 테트라하이드로퀴놀린 유도체
PE20011212A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides
AR062299A1 (es) Derivados de bencimidazol
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende
PE74899A1 (es) Derivados de ergolina
PE20001549A1 (es) Derivados de bifenilo como antagonistas del receptor de neuroquinina 1
PE20030539A1 (es) Derivados de piperazina antagonistas de los receptores de somatostatina sst1
EA200001184A1 (ru) Фенилсульфонамидфенилэтиламины, полезные в качестве допаминовых рецепторов

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed